ABT – 199 (Venetoclax)
ABT-199, also known as Venetoclax was discovered by an Australian team of Melbourne-based researchers, shows great promise for people with different subtypes of lymphoma.
Venetoclax is a targeted therapy medicine used in the treatment of CLL with a promising outlook in treatment of other subtypes of lymphoma in the future. Venetoclax works by targeting a specific protein in your blood called BCL-2 which is a protein that may build up in your body when you have CLL and prevent CLL cells from selfdestruction naturally.
Venetoclax is an oral tablet that you take every day.
Venetoclax may have the following side effects:
- Lowered blood counts
- Upper respiratory tract infection
Venetoclax is approved by the TGA and is being considered for listing and approval with the PBS.